Published in J Med Chem on March 12, 2009
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Diversification of TAM receptor tyrosine kinase function. Nat Immunol (2014) 2.12
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.45
Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe (2013) 1.42
Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res (2016) 1.41
MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer (2013) 1.17
AXL kinase as a novel target for cancer therapy. Oncotarget (2014) 1.14
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther (2011) 1.06
UNC1062, a new and potent Mer inhibitor. Eur J Med Chem (2013) 1.03
Affinity reagents that target a specific inactive form of protein kinases. Chem Biol (2010) 1.03
Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov (2013) 1.00
Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest (2014) 1.00
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem (2014) 0.99
IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. Carcinogenesis (2011) 0.96
TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog (2011) 0.94
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia (2014) 0.87
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer (2012) 0.86
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res (2013) 0.84
Global survey of the immunomodulatory potential of common drugs. Nat Chem Biol (2017) 0.83
Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors. J Comput Aided Mol Des (2011) 0.82
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol Ther (2014) 0.81
Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells. Cell Death Dis (2015) 0.80
The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. Curr Signal Transduct Ther (2011) 0.79
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis (2012) 0.79
Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal (2016) 0.79
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res (2015) 0.78
A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene (2015) 0.78
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. Oncotarget (2016) 0.78
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Med Chem Lett (2014) 0.77
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget (2015) 0.77
Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. Am J Cancer Res (2016) 0.77
Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes Cancer (2016) 0.75
Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia. Cell Rep (2017) 0.75
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget (2016) 0.75
Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. Eur J Med Chem (2016) 0.75
2-Aminopyridines via reaction of pyridine N-oxides and activated isocyanides. J Org Chem (2014) 0.75
AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckl) (2015) 0.75
Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response. Cancers (Basel) (2016) 0.75
Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer. Genes Cancer (2017) 0.75
HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling. Oncotarget (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Habitat-Lite: a GSC case study based on free text terms for environmental metadata. OMICS (2008) 4.40
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res (2006) 3.28
Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science (2010) 3.13
The MITRE Identification Scrubber Toolkit: design, training, and assessment. Int J Med Inform (2010) 2.29
Practice-based versus telemedicine-based collaborative care for depression in rural federally qualified health centers: a pragmatic randomized comparative effectiveness trial. Am J Psychiatry (2013) 2.21
Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res (2006) 2.21
Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol (2008) 2.21
The role of barren stalk1 in the architecture of maize. Nature (2004) 2.15
Two-dimensional boron monolayer sheets. ACS Nano (2012) 2.15
Craniocerebral maduromycosis. J Neurosurg Pediatr (2012) 2.01
The control of spikelet meristem identity by the branched silkless1 gene in maize. Science (2002) 2.00
Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene (2005) 1.96
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res (2007) 1.82
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Cell lineage mapping of taste bud cells and keratinocytes in the mouse tongue and soft palate. Stem Cells (2009) 1.80
Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res (2011) 1.76
A novel class of Helitron-related transposable elements in maize contain portions of multiple pseudogenes. Plant Mol Biol (2005) 1.73
Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol (2010) 1.71
The Relationship between auxin transport and maize branching. Plant Physiol (2008) 1.68
sparse inflorescence1 encodes a monocot-specific YUCCA-like gene required for vegetative and reproductive development in maize. Proc Natl Acad Sci U S A (2008) 1.64
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther (2013) 1.62
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
A conserved mechanism of bract suppression in the grass family. Plant Cell (2010) 1.59
Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem (2002) 1.59
ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis (2005) 1.59
Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent recycling of integrin beta1 to control cell migration. Dev Cell (2005) 1.58
Duplicate FLORICAULA/LEAFY homologs zfl1 and zfl2 control inflorescence architecture and flower patterning in maize. Development (2003) 1.58
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res (2008) 1.57
Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett (2006) 1.57
Conservation of B-class floral homeotic gene function between maize and Arabidopsis. Development (2004) 1.55
Endoscopic capsule placement improves the completion rate of small-bowel capsule endoscopy and increases diagnostic yield. Gastrointest Endosc (2010) 1.55
Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope (2009) 1.54
Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem (2002) 1.50
Adrenal myelolipoma associated with hyperandrogenemia. Int J Urol (2012) 1.46
Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res (2006) 1.44
A randomized trial of telemedicine-based collaborative care for depression. J Gen Intern Med (2007) 1.44
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results. Chin Med J (Engl) (2010) 1.40
Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther (2006) 1.39
Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry. Chin Med J (Engl) (2009) 1.39
An ACAP1-containing clathrin coat complex for endocytic recycling. J Cell Biol (2007) 1.38
Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis (2006) 1.36
Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. Free Radic Biol Med (2004) 1.36
Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J Biochem Mol Biol (2005) 1.33
Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry (2008) 1.27
Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis (2003) 1.24
Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res (2010) 1.22
Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci (2006) 1.22
The maize mutant barren stalk1 is defective in axillary meristem development. Am J Bot (2002) 1.21
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther (2005) 1.20
Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol (2008) 1.19
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect (2013) 1.19
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem (2002) 1.18
Occupation is more important than rural or urban residence in explaining the prevalence of metabolic and cardiovascular disease risk in Guatemalan adults. J Nutr (2007) 1.18
Trends in kinase selectivity: insights for target class-focused library screening. J Med Chem (2010) 1.18
Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell (2005) 1.15
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther (2008) 1.15
The control of axillary meristem fate in the maize ramosa pathway. Development (2010) 1.14
Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains. J Am Chem Soc (2002) 1.13
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology (2006) 1.13
A prospective study on evaluating the diagnostic yield of video capsule endoscopy followed by directed double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. Dig Dis Sci (2009) 1.12
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther (2010) 1.09
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. J Med Chem (2007) 1.08
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. J Med Chem (2004) 1.08
Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res (2007) 1.08